• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Iterum Therapeutics Announces Publication of REASSURE Trial in NEJM Evidence

    6/25/25 7:00:00 AM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ITRM alert in real time by email

    DUBLIN and CHICAGO, June 25, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company" or "Iterum"), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported that NEJM Evidence published results from its REASSURE (REnewed ASsessment of Sulopenem in uUTI caused by Resistant Enterobacterales) Phase 3 clinical trial comparing oral sulopenem (sulopenem etzadroxil combined with probenecid in a bilayer tablet) to oral Augmentin® (amoxicillin/clavulanate) in adult women with uncomplicated urinary tract infections (uUTIs) https://evidence.nejm.org/doi/full/10.1056/EVIDoa2400414.

    "We are very pleased that NEJM Evidence have published the results from the REASSURE trial," said Corey Fishman, Iterum's Chief Executive Officer. "This article highlights the need for new antibiotics, like ORLYNVAH™, for the treatment of uUTI given the increasing rates of multidrug resistance to the currently available antibiotics. We expect ORLYNVAHTM to be available to treat women with hard-to-treat infections in the next quarter."

    About REASSURE

    The REASSURE trial was designed as a non-inferiority (10% margin) trial comparing oral sulopenem and Augmentin® in the Augmentin®-susceptible population and was entitled "A prospective, Phase 3, randomized, multi-center, double-blind study of the efficacy, tolerability, and safety of oral sulopenem etzadroxil/probenecid versus oral amoxicillin/clavulanate for treatment of uncomplicated urinary tract infections (uUTI) in adult women." If the lower bound of the 95% CI is greater than -10%, non-inferiority of oral sulopenem over Augmentin® would be concluded. If the lower bound of the 95% CI is greater than 0%, superiority of oral sulopenem over Augmentin® would be concluded. Patients were randomized to receive either oral sulopenem twice daily for five days or Augmentin® twice daily for five days. The primary endpoint was the overall response (clinical and microbiologic combined response) at Day 12 (+/- 1 day) (TOC visit) of the trial. The trial enrolled 2,222 patients and was conducted under a SPA agreement with the FDA.

    9.2% of REASSURE patients in the primary population (microbiologic-modified intent-to-treat population), the combined population of patients with a positive baseline urine culture and without regard to amoxicillin/clavulanate susceptibility, had a baseline pathogen resistant to three or more classes of antibiotics.

    Results from REASSURE demonstrated that oral sulopenem was non-inferior to Augmentin® with respect to the trial's primary endpoint, overall response (combined clinical cure plus microbiologic eradication) at the test-of-cure (TOC) visit in the microbiological-modified-intent-to-treat susceptible (m-MITTS) population. Oral sulopenem showed overall success in 61.7% of patients compared to 55.0% for Augmentin®, demonstrating statistically significant superiority of oral sulopenem versus Augmentin®.

    On Oct. 25, 2024 the U.S. Food and Drug Administration (FDA) approved Iterum's new drug application for ORLYNVAH™ (sulopenem etzadroxil and probenecid) for the treatment of uncomplicated urinary tract infections (uUTIs) caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women who have limited or no alternative oral antibacterial treatment options.

    The FDA approval of ORLYNVAH™ was based on a clinical development program supported by a robust data package from two pivotal, Phase 3 clinical trials, including REASSURE.

    About Urinary Tract Infections (UTIs)

    UTIs are among the most common bacterial infections encountered in the community. There are approximately 15 million emergency room and office visits for symptoms of UTIs and over 40 million total prescriptions for uUTIs in the United States annually, with approximately two-thirds or 26 million of those prescriptions written for patients that are at elevated risk for treatment failure, based on market research. We estimate that approximately 30% of uUTIs in the United States are caused by quinolone non-susceptible pathogens, and approximately 1% of infections are caused by pathogens that are resistant to all commonly available classes of oral antibiotics. As a result, the treatment of UTIs has become more challenging because of the development of resistance by pathogens responsible for these infections. uUTIs are infections of the bladder occurring in women. Half (50%) of all women experience at least one uUTI at some point in their lives.

    About Iterum Therapeutics plc

    Iterum is focused on delivering differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum is advancing the development of its first compound, sulopenem, a novel penem anti-infective compound, with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum has received approval of its NDA for ORLYNVAH™ (oral sulopenem) for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women with limited or no alternative oral antibacterial treatment options by the FDA and has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications. For more information, please visit www.iterumtx.com.

    About ORLYNVAH™

    ORLYNVAH™ is a novel oral penem antibiotic for the treatment of uUTIs. ORLYNVAH™ possesses potent activity against species of Enterobacterales including those that encode extended spectrum beta-lactamase (ESBL) or AmpC-type beta-lactamases that confer resistance to third generation cephalosporins.

    Cautionary Note Regarding Forward-looking Statements

    This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding Iterum's plans, strategies and prospects for its business, including the development, therapeutic and market potential of ORLYNVAH™, and Iterum's ability to prepare and implement commercialization plans for ORLYNVAH™ and to bring ORLYNVAHTM to market in the U.S. in the next quarter. In some cases, forward-looking statements can be identified by words such as "may," "believes," "intends," "seeks," "anticipates," "plans," "estimates," "expects," "should," "assumes," "continues," "could," "would," "will," "future," "potential" or the negative of these or similar terms and phrases. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Iterum's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include all matters that are not historical facts. Actual future results may be materially different from what is expected due to factors largely outside Iterum's control, including Iterum's ability to raise sufficient capital and successfully prepare and implement commercialization plans for ORLYNVAH™ with its commercialization partner, EVERSANA, including Iterum's ability to, with the support of EVERSANA, build and maintain a sales force and prepare for a potential commercial launch of ORLYNVAH™, the ability of shareholders and other stakeholders to realize any value or recovery as part of a wind down process if Iterum is unsuccessful at implementing commercialization plans for ORLYNVAH™, the market opportunity for and the potential market acceptance of ORLYNVAH™ for uUTIs caused by certain designated microorganisms in adult women who have limited or no alternative oral antibacterial treatment options, Iterum's ability to continue as a going concern, uncertainties inherent in the conduct of clinical and non-clinical development, changes in regulatory requirements or decisions of regulatory authorities, the timing or likelihood of regulatory filings and approvals, changes in public policy or legislation, commercialization plans and timelines, the actions of third-party clinical research organizations, suppliers and manufacturers, the accuracy of Iterum's expectations regarding how far into the future Iterum's cash on hand will fund Iterum's ongoing operations, Iterum's ability to maintain its listing on the Nasdaq Capital Market and other factors discussed under the caption "Risk Factors" in its Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025, and other documents filed with the Securities and Exchange Commission from time to time. Forward-looking statements represent Iterum's beliefs and assumptions only as of the date of this press release. Except as required by law, Iterum assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

    Investor Contact:

    Judy Matthews

    Chief Financial Officer

    312 778 6073



    Primary Logo

    Get the next $ITRM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ITRM

    DatePrice TargetRatingAnalyst
    7/27/2021Sell → Hold
    Gabelli & Co.
    7/26/2021Buy → Neutral
    HC Wainwright & Co.
    More analyst ratings

    $ITRM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Iterum Therapeutics upgraded by Gabelli & Co.

      Gabelli & Co. upgraded Iterum Therapeutics from Sell to Hold

      7/27/21 11:35:29 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iterum Therapeutics downgraded by HC Wainwright & Co.

      HC Wainwright & Co. downgraded Iterum Therapeutics from Buy to Neutral

      7/26/21 12:19:14 PM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iterum Therapeutics upgraded by Gabelli & Co

      Gabelli & Co upgraded Iterum Therapeutics from Sell to Hold

      5/28/21 8:38:55 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ITRM
    SEC Filings

    See more
    • Iterum Therapeutics plc filed SEC Form 8-K: Entry into a Material Definitive Agreement

      8-K - Iterum Therapeutics plc (0001659323) (Filer)

      6/11/25 7:15:25 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iterum Therapeutics plc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Iterum Therapeutics plc (0001659323) (Filer)

      5/19/25 7:15:09 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Iterum Therapeutics plc

      10-Q - Iterum Therapeutics plc (0001659323) (Filer)

      5/13/25 7:30:25 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ITRM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Commercial Officer Coyne Christine

      4 - Iterum Therapeutics plc (0001659323) (Issuer)

      7/3/25 4:16:04 PM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Coyne Christine

      3 - Iterum Therapeutics plc (0001659323) (Issuer)

      7/3/25 4:15:09 PM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Whalen Joseph John

      3 - Iterum Therapeutics plc (0001659323) (Issuer)

      3/18/25 8:00:04 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ITRM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      DUBLIN and CHICAGO, July 02, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) ("Iterum" or the "Company"), a company committed to delivering next generation oral and IV antibiotics to address infections caused by multi-drug resistant pathogens, today announced that it has granted a non-statutory share option to purchase an aggregate of 200,000 ordinary shares of Iterum to Christine Coyne, Iterum's newly appointed Chief Commercial Officer. This grant was awarded pursuant to the Nasdaq inducement grant exception as a component of new hire employment compensation. The share option was granted effective July 1, 2025, with an exercise price of $0.97 per share, which is equal to t

      7/2/25 4:30:00 PM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth

      DUBLIN and CHICAGO, June 30, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) ("Iterum" or the "Company"), a company committed to delivering next generation oral and IV antibiotics to address infections caused by multi-drug resistant pathogens, today announced the appointment of Christine Coyne to the newly created position of Chief Commercial Officer. In this role, Ms. Coyne will lead all commercial efforts for Iterum, including the upcoming launch of ORLYNVAH™ in the United States, as well as future commercialization activities across new products and markets. "We are delighted to welcome Christine to the Iterum leadership team at such a pivotal time for the company," said

      6/30/25 7:00:00 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iterum Therapeutics Announces Publication of REASSURE Trial in NEJM Evidence

      DUBLIN and CHICAGO, June 25, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company" or "Iterum"), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported that NEJM Evidence published results from its REASSURE (REnewed ASsessment of Sulopenem in uUTI caused by Resistant Enterobacterales) Phase 3 clinical trial comparing oral sulopenem (sulopenem etzadroxil combined with probenecid in a bilayer tablet) to oral Augmentin® (amoxicillin/clavulanate) in adult women with uncomplicated urinary tract infections (uUTIs) https://evidence.nejm.org/

      6/25/25 7:00:00 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ITRM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Dunne Michael W. bought $35,000 worth of Ordinary Shares (25,000 units at $1.40), increasing direct ownership by 28% to 113,754 units (SEC Form 4)

      4 - Iterum Therapeutics plc (0001659323) (Issuer)

      12/27/23 9:00:06 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dunne Michael W. bought $18,442 worth of Ordinary Shares (10,000 units at $1.84), increasing direct ownership by 13% to 88,754 units (SEC Form 4)

      4 - Iterum Therapeutics plc (0001659323) (Issuer)

      12/19/23 4:15:25 PM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dunne Michael W. bought $40,690 worth of Ordinary Shares (20,000 units at $2.03), increasing direct ownership by 34% to 78,754 units (SEC Form 4)

      4 - Iterum Therapeutics plc (0001659323) (Issuer)

      11/27/23 5:00:19 PM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ITRM
    Leadership Updates

    Live Leadership Updates

    See more
    • Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth

      DUBLIN and CHICAGO, June 30, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) ("Iterum" or the "Company"), a company committed to delivering next generation oral and IV antibiotics to address infections caused by multi-drug resistant pathogens, today announced the appointment of Christine Coyne to the newly created position of Chief Commercial Officer. In this role, Ms. Coyne will lead all commercial efforts for Iterum, including the upcoming launch of ORLYNVAH™ in the United States, as well as future commercialization activities across new products and markets. "We are delighted to welcome Christine to the Iterum leadership team at such a pivotal time for the company," said

      6/30/25 7:00:00 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iterum Therapeutics Appoints Sailaja Puttagunta, MD as Chief Medical Officer

      DUBLIN, Ireland and CHICAGO, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company" or "Iterum"), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced the appointment of Sailaja Puttagunta, M.D., to the newly created position of Chief Medical Officer, where she will oversee global clinical development and regulatory initiatives for Iterum. "We are thrilled that Sailaja is back at Iterum given her strong industry and operational leadership at a time when oral sulopenem is re-entering the clin

      12/13/21 8:00:00 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iterum Therapeutics Appoints Beth P. Hecht to Board of Directors

      Patrick Heron to leave the Board DUBLIN, Ireland and CHICAGO, March 16, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced the appointment of Beth P. Hecht to the Company’s Board of Directors replacing Patrick Heron, who announced he would be leaving the Board, effective as of March 12, 2021. Ms. Hecht will also serve as a member of the Audit Committee and Compensation Committee of the Board. “I want to thank Patrick for his leade

      3/16/21 7:30:00 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ITRM
    Financials

    Live finance-specific insights

    See more
    • Iterum Therapeutics Announces Partnership for Commercialization Services

      U.S. Commercial Launch of ORLYNVAHTM by Q4 2025; First Oral Penem Available in the U.S. Management to host a conference call at 4:30 p.m. ET today DUBLIN and CHICAGO, June 11, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company" or "Iterum"), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported that it entered into a Product Commercialization Agreement (the "Agreement") with EVERSANA Life Science Services, LLC ("EVERSANA") for the commercialization of the Company's approved product, ORLYNVAHTM.   Pursuant to the Agreement, EVERSA

      6/11/25 7:00:00 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iterum Therapeutics to Report First Quarter 2025 Financial Results on May 13, 2025

      DUBLIN, Ireland and CHICAGO, May 06, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its first quarter 2025 financial results before the open of the U.S. financial markets on Tuesday, May 13, 2025. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company's financial results and provide an update on its business. To access the call please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to Access

      5/6/25 7:00:00 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

      --ORLYNVAHTM Approved by FDA in Q4 2024— --Extended Cash Runway-- --Company to host conference call today at 8:30amET-- DUBLIN and CHICAGO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the fourth quarter and year ended December 31, 2024. "While outreach to potential strategic partners is our priority and ongoing, we have begun pre-commercialization work to ensure ORLYNVAHTM is made available to patients as soon as possible to address the substantial u

      2/7/25 7:00:00 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ITRM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Iterum Therapeutics plc

      SC 13G/A - Iterum Therapeutics plc (0001659323) (Subject)

      11/14/24 7:54:21 PM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Iterum Therapeutics plc

      SC 13G - Iterum Therapeutics plc (0001659323) (Subject)

      11/14/24 3:31:48 PM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Iterum Therapeutics plc

      SC 13G - Iterum Therapeutics plc (0001659323) (Subject)

      1/31/24 4:55:45 PM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care